Article
Astralis Ltd., partnered with SkyPharma PLC, has initiated a phase I clinical trial in the United States for Psoraxine, a new injectable treatment for moderate psoriasis.
The Weekly Roundup: December 16-20
The Cutaneous Connection: Intervening in AD Progression for Pediatric Patients
Dermatology Times December 2024 Recap
The Cutaneous Connection: Navigating Systemic Therapies in Atopic Dermatitis
How OJM Group Can Help Dermatologists Reach Their Financial Goals in 2025 and Beyond
Interview Intersection: Expert Interviews From December 2024